Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cyclosporine
Find trials that include:  Any drugs shown
Results 1-25 of 31 for your search:
Start Over
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy Using Sirolimus in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, CPRC #2005LS075, HS# 0511M77206, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2056.00, NCI-2010-00237, FHCRC-2056.00, 6171, NCT00397813
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, 2010, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, 2275, FHCRC-2275.00, IR-6800, NCT00796068
Treosulfan and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Nonmalignant Inherited Disorders
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 55
Trial IDs: 2256.00, NCI-2010-01277, FHCRC-2256.00, IR-6935, NCT00919503
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: not specified
Trial IDs: 2430.00, NCI-2010-02247, NCT01252667
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2398.00, NCI-2011-01189, NCT01434472
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 0 to 75
Trial IDs: 2546.00, NCI-2011-03828, NCT01527045
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients with High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
Ibritumomab Tiuxetan before Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 to 75
Trial IDs: UCDCC#233, NCI-2012-02753, NCT01811368
CD8+ Memory T-Cells as Consolidative Therapy after Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients with Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB-33058 / BMT288, NCI-2015-00567, 33058, 351, BMT288, IRB-33058, NCT02424968
Vorinostat, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease after Unrelated Donor Stem Cell Transplant in Patients with Malignant or Non-Malignant Hematological Conditions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: UMCC 2012.047, NCI-2016-00134, NCT01790568
Donor Stem Cell Transplant in Treating Patients with DOCK8 Deficiency
Status: Active
Phase: Phase I
Type: Treatment
Age: 8 to 40
Trial IDs: 10-C-0174, NCI-2013-01462, 100174, P10665, NCT01176006
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and over
Trial IDs: 2468.00, NCI-2011-00150, 2468, 2468.00A, NCT01300572
Start Over